SR-4835 is a Highly Selective and ATP Competitive Dual Inhibitor of CDK12/CDK13
Breast cancer is the most frequently diagnosed cancer of women worldwide. The feature of triple-negative breast cancers (TNBCs) is the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal…